Drug Approval | October 04, 2024
Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
This is used to treat central diabetes insipidus and bedwetting
This is used to treat central diabetes insipidus and bedwetting
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
The inspection conducted by EDQM at its Visakhapatnam facility
He holds a Master’s in Management from the National University of Singapore
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
The inspection concluded with the issuance of a form 483 with five observations
Subscribe To Our Newsletter & Stay Updated
